Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 278.38M | 263.24M | 284.68M | 203.88M | 150.41M |
Gross Profit | 79.78M | 76.70M | 82.93M | 53.12M | 38.85M |
EBITDA | 24.51M | 24.51M | 29.53M | 6.97M | -9.89M |
Net Income | 13.33M | 16.83M | 20.89M | 10.99M | -8.87M |
Balance Sheet | |||||
Total Assets | 132.08M | 120.48M | 87.96M | 72.85M | 68.34M |
Cash, Cash Equivalents and Short-Term Investments | 4.73M | 6.28M | 339.00K | 235.00K | 734.00K |
Total Debt | 42.18M | 34.00M | 13.76M | 18.22M | 16.77M |
Total Liabilities | 98.59M | 94.69M | 56.00M | 46.88M | 46.10M |
Stockholders Equity | 33.48M | 25.79M | 31.96M | 25.97M | 22.24M |
Cash Flow | |||||
Free Cash Flow | 3.60M | 9.55M | 27.55M | 347.00K | 24.74M |
Operating Cash Flow | 6.17M | 12.48M | 28.44M | 915.00K | 25.20M |
Investing Cash Flow | -2.57M | -2.54M | -4.98M | 6.29M | -419.00K |
Financing Cash Flow | -4.83M | -3.85M | -23.13M | -7.55M | -25.63M |
On May 6, 2025, RCM Technologies’ Compensation Committee approved grants of up to 2,904 performance stock units to Michael Saks, Division President of Health Care Services, under the company’s 2014 Omnibus Equity Compensation Plan. The vesting of these units is contingent upon the achievement of specific operating income levels during the performance period from December 29, 2024, to January 3, 2026, with provisions for accelerated vesting in the event of a Change in Control.